Together, these results provide a rationale for targeting EGF-like factors (HB-EGF, AREG and TGF-α) and proteases (MMP1 and ADAMTS1) in tumour cells, as well as EGFR in osteoblasts for controlling osteolytic bone metastasis of breast cancer. This evidence concerns the gene EGFR and breast carcinoma.